Select Language:
Popular weight-loss drugs like Ozempic, Wegovy, Saxenda, and Mounjaro are transforming how healthcare providers tackle obesity and type 2 diabetes. Millions worldwide are using these medications to curb appetite, shed pounds, and better manage blood sugar levels. A new large-scale study presented at the European Congress on Obesity (ECO 2026) indicates that the amount of weight individuals lose while on these drugs could significantly influence their long-term health.
Researchers discovered that patients who achieved more substantial weight loss experienced substantially lower risks of obesity-related conditions such as sleep apnea, chronic kidney disease, osteoarthritis, and heart failure. Conversely, those who gained weight after starting treatment tended to face worse health outcomes. The study was led by Professor John Wilding from the University of Liverpool in the UK.
These GLP-1 medications mimic natural hormones that regulate hunger and digestion. They slow gastric emptying, prolong feelings of fullness, and reduce appetite. Some also improve blood sugar control, which is particularly important for individuals with type 2 diabetes. While clinical trials have already proven these drugs can produce notable weight loss, researchers aimed to understand their effects in real-world healthcare settings, where patients might stop treatment or regain weight.
Using data from the Optum Market Clarity database—an extensive U.S. healthcare records and insurance claims repository—the team analyzed nearly 90,000 patients who started GLP-1 therapy between January 2021 and June 2024. Most of these individuals used semaglutide medications like Ozempic or Wegovy, with others on tirzepatide (sold as Mounjaro) or liraglutide (Saxenda).
At the start, the average patient was about 57.5 years old with a BMI of 34.7, placing them in the obese category. About 61% also had type 2 diabetes. The scientists tracked changes in body mass index (BMI) during the first year of treatment, a standard measure estimating body fat based on height and weight. They then examined how these changes correlated with the development of several serious obesity-related health issues, including joint degeneration, kidney problems, sleep apnea, and heart failure.
A notable finding was that nearly half of all patients discontinued their medication for at least two months within the first year. Despite this, the team analyzed outcomes based on whether individuals lost or gained weight during their treatment period. The data revealed a clear trend: greater weight loss was linked to healthier results.
Approximately 15.8% of patients reduced their BMI by 15% or more. Compared to those who lost less than 5%, these individuals had significantly lower risks of conditions like osteoarthritis, with a 37% reduction; chronic kidney disease, which dropped by 30%; sleep apnea, decreasing by 69%; and heart failure, which saw a 32% reduction—though this last figure wasn’t statistically conclusive.
The study also uncovered concerning results for those who gained weight. Compared to those who lost less than 5%, weight gain was associated with a 10% higher risk of osteoarthritis, a 14% increase in chronic kidney disease risk, a 22% rise in sleep apnea, and a striking 69% higher chance of developing heart failure. The increased risks for sleep apnea and heart failure were particularly significant.
These findings highlight how closely obesity is tied to numerous chronic health conditions. Excess body weight puts strain on joints, impairs breathing, promotes inflammation, stresses the heart, and contributes to metabolic issues that harm organs over time. Consequently, weight loss can offer widespread health benefits beyond cosmetic improvements or blood sugar control.
However, the study also underscores the challenge of maintaining long-term treatment with GLP-1 medications. Many patients stop due to side effects like nausea, gastrointestinal discomfort, high costs, insurance limitations, or difficulty sticking to lifestyle changes. Ongoing research aims to determine whether sustained weight loss is possible after stopping these drugs and whether prolonged use could provide even greater health protections.
It’s important to note that while the study shows a strong association between weight loss and improved health outcomes, it doesn’t establish a direct causal link—that is, it doesn’t definitively prove the medications alone caused the reduced disease risks. Instead, it suggests that greater weight loss generally correlates with better health.
These insights may motivate healthcare providers to focus more on supporting sustained weight loss through medication and lifestyle strategies. If you’re interested in weight loss options, consider reviewing studies on how hop extract might reduce belly fat, or how early time-restricted eating can aid weight loss. Additional research indicates that the Mediterranean diet is highly effective at reducing abdominal fat, while the ketogenic diet may help with weight management and blood sugar control in diabetes.
Source: University of Liverpool.
ChatGPT
Perplexity
Gemini AI
Grok AI
